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S U M M A R Y
Macrophage activation syndrome (MAS) is a systemic disorder with a high mortality, commonly
associated with rheumatological conditions, but which can also occur as a complication of several
infections. Here we present a case of MAS following Acinetobacter baumannii sepsis. Early institution of
therapy with prednisolone, cyclosporine, colistin, and polymyxin resulted in a prompt clinical recovery.
There are very few reported cases of Acinetobacter-related MAS that have been successfully treated.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Acinetobacter baumannii is usually regarded as an opportunistic
pathogen of low virulence, but it may produce a wide variety of
serious hospital-acquired infections, like pneumonia and bacter-
emia. It has recently been found to be associated with several
community-acquired and multidrug-resistant infections. We
present a case of macrophage activation syndrome (MAS)
following septicemia caused by multidrug-resistant A. baumannii,
which was successfully treated.
2. Case report
A 28-year-old male, chronic alcoholic and heavy smoker, with a
history of recent intensive care unit admission, was referred to our
tertiary care hospital with a provisional diagnosis of fever of
unknown origin (FUO). He had had 3 weeks of unrelenting fever,
not responding to conventional antibiotics. On examination, he
was found to be febrile (39.1 8C) and had a pulse rate of 110/min
and blood pressure of 90/70 mmHg. He was tachypneic, pale, and
icteric. The patient had bilaterally palpable, non-tender, ﬁrm
cervical, axillary, and inguinal lymph nodes. Abdominal examina-
tion revealed non-tender, ﬁrm hepatomegaly and splenomegaly. A
hemogram showed pancytopenia with a progressively declining
hemoglobin level and leukocyte and platelet counts. Liver function
tests revealed elevated prothrombin and activated thromboplastin
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(EBV), viral markers for hepatitis A, B, C, and E and HIV, and tests for
malaria and syphilis were all negative. The anti-nuclear antibody
proﬁle and rheumatoid factor were unremarkable. The serum
ferritin level was markedly elevated at 41 569 pmol/l and the
fasting lipid proﬁle showed hypertriglyceridemia at 6.994 mmol/l.
Serum ﬁbrinogen was low at 0.38 mmol/l. A peripheral smear
revealed pancytopenia. Flow cytometry showed decreased natural
killer (NK) cell activity. A lymph node biopsy showed extensive
necrosis and macrophages showing hemophagocytosis. Bone
marrow study showed an increase in macrophages, with some
of the macrophages showing hemophagocytosis and phagocytosed
necrotic debris, and local collections of histiocytes (Figure 1). No
granulomas or malignant cells were seen. Gram-negative cocco-
bacilli – A. baumannii – sensitive to colistin and polymyxin B and
resistant to penicillins, cephalosporins, and meropenem, were
isolated from bone marrow and blood cultures. A diagnosis of MAS
secondary to Acinetobacter sepsis was made, as per the diagnostic
criteria that include fever >38.5 8C for 7 or more days,
splenomegaly >3 cm below the left costal margin, cytopenia
involving two or more cell lines (hemoglobin <90 g/l, or absolute
neutrophil count <1  109/l, or platelet count <100  109/l),
hypertriglyceridemia (>2 mmol/l), hypoﬁbrinogenemia
(<0.44 mmol/l), and hemophagocytosis in bone marrow, lymph
node, or spleen biopsy, with no evidence of malignancy.
We started the patient on immunosuppressants (prednisolone
1 mg/kg and cyclosporine 5 mg/kg) and antibiotics (colistin
2.5 mg/kg/day and polymyxin 15 000 IU/kg/day). His clinical
status dramatically improved and his blood values including blood
counts,liver function tests,coagulation proﬁle and serum ferritin
returned to normal in 2 days.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Bone marrow (hematoxylin and eosin staining) showing hemophagocytosis
with activated macrophage engulﬁng a neutrophil, with intracellular debris.
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MAS or secondary hemophagocytic lymphohistiocytosis (HLH)
is a severe form of systemic inﬂammatory response syndrome
(SIRS) and was ﬁrst described in 1985 by Hadchouel et al. in
systemic onset juvenile rheumatoid arthritis (S-JRA).1 It is a rare
syndrome, which is not often suspected clinically. The condition is
potentially fatal, mostly due to a delay in diagnosis.
MAS is associated with infections, autoimmune disorders, and
malignancies.2 The most common infections associated with MAS
are viral, mostly EBV and cytomegalovirus (CMV).2,3 It may also
coincide with various bacterial, parasitic, and fungal infections.
The central pathophysiology in MAS is cytokine dysfunction,2,4
resulting in an uncontrolled accumulation of activated T-lympho-
cytes and activated histiocytes (macrophages) in many organs, and
active hemophagocytosis by normal-appearing macrophages.
There is impaired cytotoxic function of NK cells and CD8+ T cells,
leading to persistence of the infecting organism, causing persistent
T-cell stimulation. Clinical features include continuous fever,
purpura, hepatosplenomegaly, and mental status changes, with
marked cytopenias, coagulopathy, and hypoﬁbrinogenemia.4
Acinetobacter is a ubiquitous Gram-negative coccobacillus
that is typically associated with hospital-acquired infections.5 It
has traditionally been thought to cause mild to moderately severe
infections, however it has recently been shown that it can be
highly virulent with a propensity to cause invasive disease in the
non-critically ill. The organism is widely distributed in the
environment, and the rapid development of multiple antibiotic
resistance has made it a signiﬁcant nosocomial pathogen. There
has been an unprecedented increase in the incidence ofAcinetobacter infections worldwide. Patients at risk are often
critically ill with multiple comorbidities, are on prolonged courses
of antibiotics, or are those with prior colonization, as seen with
alcoholics, those admitted to ICUs, mechanically ventilated
patients, and those with indwelling catheters. Community-
acquired Acinetobacter infections typically occur in persons with
comorbidities such as alcohol abuse, chronic obstructive pulmo-
nary disease, diabetes mellitus, and smoking. The most common
manifestation of Acinetobacter infection is pneumonia, followed
by bacteremia. Only a few cases of MAS secondary to Acineto-
bacter infection have previously been reported.2
Early diagnosis and initiation of treatment is critical for a better
patient outcome. Treatment should be initiated as soon as possible,
since any delay in therapy may lead to irreversible multi-organ
failure. Treatment is usually supportive along with treatment of
the underlying disease. Steroids and immunosuppressants have a
deﬁnite role in the treatment of MAS.3 Steroids, either prednisone
(4 mg/kg/day) or dexamethasone (6 mg/m2/day), and cyclosporine
(2–5 mg/kg/day) are commonly used.
In conclusion, only a very few cases of this deadly and unique
syndrome have been diagnosed promptly and treated success-
fully. This represents one of the rare reported cases of
Acinetobacter-related MAS in the literature.
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